Smith et al provided a timely and thoughtful overview of distributional cost-effectiveness analysis (DCEA) in genomic medicine, clarifying equity-efficiency trade-offs along the “inequality staircase” and highlighting data equity and non–health outcome considerations.¹ I strongly support this agenda and offer 6 implementation-focused advances tailored to US decision contexts.